In a report released today, Robert LeBoyer from Noble Financial reiterated a Buy rating on Ocugen (OCGN – Research Report), with a price target of $5.00. The company’s shares closed yesterday at $0.40.
According to TipRanks, LeBoyer is an analyst with an average return of -10.4% and a 23.83% success rate. LeBoyer covers the Healthcare sector, focusing on stocks such as PDS Biotechnology, Tonix Pharma, and GeoVax Labs.
Currently, the analyst consensus on Ocugen is a Moderate Buy with an average price target of $5.00, a 1,140.08% upside from current levels. In a report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $5.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Based on Ocugen’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $22.93 million. In comparison, last year the company had a GAAP net loss of $19.47 million
Based on the recent corporate insider activity of 13 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of OCGN in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Ocugen, Inc. engages in the development and commercialization of therapies for eye diseases. Its pipeline of therapies includes OCU400, OCU410, OCU200, OCU100, and OCU300. The company was founded by Shankar Musunuri and Uday Kompella in 2013 and is headquartered in Malvern, PA.
Read More on OCGN:
- Ocugen Provides Business Update with Second Quarter 2023 Financial Results
- Ocugen reports Q2 EPS (10c), consensus (7c)
- Ocugen to Host Conference Call on Tuesday, August 22 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2023 Financial Results
- OCGN Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Ocugen CEO & CSO to Present at 41st Annual AAPI Convention and Scientific Assembly
